J P Morgan Chase & Co reaffirmed their neutral rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a research note released on Thursday, July 13th.

Several other analysts have also weighed in on GSK. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a buy rating to a hold rating in a research report on Wednesday, March 29th. BNP Paribas upgraded shares of GlaxoSmithKline PLC from an underperform rating to a neutral rating and decreased their target price for the company from $45.58 to $37.20 in a research report on Wednesday, April 5th. Exane BNP Paribas upgraded shares of GlaxoSmithKline PLC from an underperform rating to a neutral rating in a research report on Wednesday, April 5th. TheStreet upgraded shares of GlaxoSmithKline PLC from a c rating to a b rating in a research report on Friday, May 19th. Finally, Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a hold rating to a buy rating in a research report on Friday, May 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $46.00.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.15 on Thursday. The stock’s 50 day moving average price is $42.44 and its 200 day moving average price is $41.81. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.59. The stock has a market cap of $98.13 billion, a price-to-earnings ratio of 39.60 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/09/glaxosmithkline-plc-gsk-given-neutral-rating-at-j-p-morgan-chase-co-updated-updated-updated.html.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.89%. GlaxoSmithKline PLC’s payout ratio is currently 194.00%.

Several institutional investors have recently made changes to their positions in GSK. Bronfman E.L. Rothschild L.P. increased its position in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Heritage Trust Co bought a new position in shares of GlaxoSmithKline PLC during the first quarter worth $123,000. Finally, Westwood Holdings Group Inc. increased its position in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. 8.96% of the stock is owned by institutional investors.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.